Fazirsiran

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameFazirsiran
Drug Alias NameARO-AATTAK-999ADS-001
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionAlpha-1-antiproteinase inhibitorsRNA interference
TargetsAlpha-1-antiproteinase
Therapy Area/IndicationsHepatic Insufficiencyalpha 1-Antitrypsin Deficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesArrowhead Pharmaceuticals IncTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesArrowhead Pharmaceuticals IncTakeda Pharmaceutical Co LtdTakeda Development Center Americas Inc
Inactive CompaniesN/A
Active IndicationsHepatic Insufficiencyalpha 1-Antitrypsin Deficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A